Vertex Pharma, US92532F1003

Vertex Pharmaceuticals stock extends Genomics pact worth USD 220 million

Published on 11/18/2026 at 14:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Vertex Pharmaceuticals stock is in focus after the company extended its human-genetics research partnership. The agreement supports future precision-medicine programs.

Vertex expands its research platform

  • Genomics and Vertex extended their human-genetics collaboration by four years on November 18, 2026.
  • The partnership targets drug discovery, target validation and biomarker selection for precision medicines.
  • Vertex has held an equity investment in Genomics since 2018.
Vertex Pharma, US92532F1003, Illustration mit AI erstellt.

Vertex Pharmaceuticals extended its strategic drug discovery and validation collaboration with Genomics by four years on Wednesday, November 18, 2026, according to a Genomics announcement. The agreement continues an eight-year partnership that began in 2018 and adds another period of cooperation in human-genetics-based drug research.

Vertex Pharmaceuticals stock traded at 485.50 euros on Lang & Schwarz at 14:15 CET on Wednesday, November 18, 2026.

Research agreement targets precision medicines

The collaboration focuses on using human genetic information to discover and validate novel drug targets and to select biomarkers for precision medicines. The companies also intend to deepen their understanding of how human genetic variation affects diseases with significant unmet need.

Genomics said the potential contract value exceeds 220 million US dollars. Payments depend on research, development, regulatory and commercial milestones, while the agreement also provides for tiered royalties on future net sales of products that may result from the collaboration.

The announcement did not identify specific drug programs covered by the extended agreement. It did confirm that scientists from both companies will continue working together on research and development. For Vertex, the relationship provides access to a specialized genetics platform as the company expands its commercial and development portfolio beyond its established cystic fibrosis business.

Vertex emphasizes long-term partnership

Mark Bunnage, Vertex's executive vice president and chief scientific officer, said human genetics and the underlying biology of disease are foundational to the company's approach to discovering and developing therapies. He described Genomics as an established partner with expertise in data science and genetic insights.

Genomics said its platform includes more than 45,000 genome-wide association studies and trillions of data rows. The company also said it has identified more than 100 drug targets using its analytical tools. These figures describe the partner's platform and do not represent additional Vertex products or approved medicines.

Vertex has held an equity investment in Genomics since 2018. The extended collaboration therefore combines a continuing commercial relationship with an existing financial interest in the privately held technology company.

Vertex Pharmaceuticals

  • Company: Vertex Pharmaceuticals Incorporated
  • ISIN: US92532F1003
  • Ticker: VRTX
  • Lang & Schwarz quote: 485.50 euros at 14:15 CET on November 18, 2026
  • Partnership: Four-year extension with Genomics announced November 18, 2026

US equities remain part of the wider S&P 500 market environment.

More news and analyses on Vertex Pharmaceuticals stock

Disclaimer...
en | US92532F1003 | VERTEX PHARMA | boerse | 70531073 | bgmi